ENANTA PHARMACEUTICALS INC 8-K

What Happened
Enanta Pharmaceuticals, Inc. (ENTA) filed a Form 8-K on March 12, 2026 reporting that its stockholders on March 11, 2026 approved an amendment to the company's 2019 Equity Incentive Plan. The amendment increases the number of shares reserved for issuance under the plan by 1,600,000 shares. The amended plan is included as Exhibit 10.1 to the 8-K. The report is signed by President and CEO Jay R. Luly, Ph.D.

Key Details

• Vote type: Submission of Matters to a Vote of Security Holders (Item 5.07) — stockholder approval occurred on March 11, 2026.
• Plan amended: 2019 Equity Incentive Plan increased by 1,600,000 shares.
• Filing: Current Report on Form 8-K filed March 12, 2026; amended plan attached as Exhibit 10.1.
• Executive signature: Report signed by Jay R. Luly, Ph.D., President & CEO.

Why It Matters
This amendment expands the pool of shares available for grants to employees, officers and directors, which the company can use for compensation, hiring and retention. For investors, the key implications are potential future dilution if the new shares are granted and issued; the filing itself does not report any immediate grant amounts or financial results. There were no earnings or other financial disclosures in this 8-K.